http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
-
MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing
-
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
-
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
-
Merck (MRK) and EyeBio Initiate Phase 2b/3 Trial for Restoret
-
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
-
MilliporeSigma Receives Industry First EXCiPACT Certification for Cell Culture Media Manufacturing
-
Merck (MRK) Announces EU Approval of KEYTRUDA Plus Padcev as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
-
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Merck (MRK) Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
-
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
-
Merck (MRK) Announces Phase 3 Trial Initiation for Bomedemstat
-
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
-
Merck (MRK) Receives European Commission Approval for WINREVAIR (sotatercept)
-
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Fu
-
Merck (MRK) to Acquire CN201 from Curon Biopharmaceutical
-
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
-
Merck (MRK) Provides Update on Phase 3 KeyVibe-008 Trial of an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab
-
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
-
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
-
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
-
MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering
-
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
-
Merck Announces Second-Quarter 2024 Financial Results
-
Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
-
Merck Announces Fourth-Quarter 2024 Dividend
-
Merck (MRK) Reports Topline Results from Phase 2b/3 Trial of Clesrovimab
-
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
-
10 policies if Trump wins and stock implications: Jefferies
-
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
-
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
-
Merck (MRK) Completes Acquisition of EyeBio
-
Merck Completes Acquisition of EyeBio
-
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
-
Merck (MRK) and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat
-
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Pr
-
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
-
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
-
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
-
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
-
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
-
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
-
MilliporeSigma and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s Research
-
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
-
Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
-
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
-
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant
